SPY415.21-2.05 -0.49%
DIA340.75-1.11 -0.32%
IXIC13,914.77-137.58 -0.98%

BRIEF-ProQR Therapeutics To Present Results From Phase 1/2 Trial Of Qr-421A For Usher Syndrome

· 03/17/2021 07:46
BRIEF-ProQR Therapeutics To Present Results From Phase 1/2 Trial Of Qr-421A For Usher Syndrome

- ProQR Therapeutics NV PRQR.O:

  • PROQR TO PRESENT RESULTS FROM PHASE 1/2 TRIAL OF QR-421A FOR USHER SYNDROME

Source text for Eikon: ID:nGNX9Sx8Xf

Further company coverage: PRQR.O


((Reuters.Briefs@thomsonreuters.com;))